GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Scienture Holdings Inc (NAS:SCNX) » Definitions » Gross Margin %

SCNX (Scienture Holdings) Gross Margin % : 6.15% (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Scienture Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Scienture Holdings's Gross Profit for the three months ended in Sep. 2024 was $0.00 Mil. Scienture Holdings's Revenue for the three months ended in Sep. 2024 was $0.07 Mil. Therefore, Scienture Holdings's Gross Margin % for the quarter that ended in Sep. 2024 was 6.15%.

Warning Sign:

Scienture Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -14.3%.


The historical rank and industry rank for Scienture Holdings's Gross Margin % or its related term are showing as below:

SCNX' s Gross Margin % Range Over the Past 10 Years
Min: 31.41   Med: 65.51   Max: 99.36
Current: 34.24


During the past 13 years, the highest Gross Margin % of Scienture Holdings was 99.36%. The lowest was 31.41%. And the median was 65.51%.

SCNX's Gross Margin % is ranked worse than
59.52% of 620 companies
in the Healthcare Providers & Services industry
Industry Median: 40.985 vs SCNX: 34.24

Scienture Holdings had a gross margin of 6.15% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Scienture Holdings was -14.30% per year.


Scienture Holdings Gross Margin % Historical Data

The historical data trend for Scienture Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scienture Holdings Gross Margin % Chart

Scienture Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.51 33.33 47.99 53.84 31.41

Scienture Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.20 34.60 - -5.26 6.15

Competitive Comparison of Scienture Holdings's Gross Margin %

For the Pharmaceutical Retailers subindustry, Scienture Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scienture Holdings's Gross Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Scienture Holdings's Gross Margin % falls into.



Scienture Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Scienture Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=2.6 / 8.272
=(Revenue - Cost of Goods Sold) / Revenue
=(8.272 - 5.674) / 8.272
=31.41 %

Scienture Holdings's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0 / 0.065
=(Revenue - Cost of Goods Sold) / Revenue
=(0.065 - 0.061) / 0.065
=6.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Scienture Holdings  (NAS:SCNX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Scienture Holdings had a gross margin of 6.15% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Scienture Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Scienture Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scienture Holdings Business Description

Traded in Other Exchanges
N/A
Address
2420 Brunello Trace, Lutz, FL, USA, 33558
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
Executives
A. Jeffrey Newell director 645 CAMP DIXIE RD, PASCOAG RI 02859
Donald G. Fell director 17537 DARBY LANE, LUTZ FL 33558
Janet Huffman officer: CFO, PAO, PFO 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526
Christine L. Jennings director 3840 LAND O' LAKES BLVD., LAND O' LAKES FL 34639
Prashant Patel director, 10 percent owner, officer: President 17537 DARBY LANE, LUTZ FL 33558
Pamela Tenaerts director PO BOX 15012, SARASOTA FL 34277
Gary Augusta director 700 NORTH BRAND BLVD., SUITE 1400, GLENDALE CA 91203
Howard A. Doss officer: CFO 17537 DARBY LANE, LUTZ FL 90067
Surendra K Ajjarapu director, 10 percent owner, officer: CEO 8604 BUTTON BUSH CT, TAMPA FL 33647
Donald V. Almeida director 1115 GUNN HIGHWAY, SUITE 202, ODESSA FL 33556
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Sandhya Ajjarapu 10 percent owner 17537 DARBY LANE, LUTZ FL 33558